Bedrijfsoverzicht
WORK Medical Technology Group LTD, ticker WOK, operates as a manufacturer and distributor of medical consumables and devices within the People's Republic of China and international markets. The company functions within the Healthcare sector, specifically the Medical Devices industry, where it provides essential equipment such as medical face masks, artery compression tourniquets, endotracheal tube holders, intubating stylets, and gu. With a market capitalization of $1.68M and an annual revenue of $9.85M, the company employs a workforce of 238 individuals. The valuation metrics indicate that this entity operates on a micro-cap scale, suggesting it is a smaller player in the broader medical device landscape with limited financial resources compared to large-cap peers. The combination of specialized manufacturing capabilities and a relatively small employee base highlights a lean operational structure focused on niche medical product lines.
Financiële gezondheid
The company reported a total revenue of $9.85M over the trailing twelve months, yet recorded a net income loss of $-1,072,667 and an EBITDA of $-1,572,952. The significant gap between the positive revenue figure and the substantial net loss reveals a cost structure where expenses, including cost of goods sold and operational overhead, vastly outweigh the gross earnings generated from sales. This financial reality is further evidenced by a free cash flow of $-5,521,727, which indicates a severe cash burn rate that constrains the company's financial flexibility and ability to fund operations without external capital injections. Margin analysis shows a gross margin of 23.8%, while the operating margin sits at -17.5% and the profit margin at -10.9%, indicating that for every dollar of revenue, the company retains only a fraction as gross profit before operating expenses erode profitability significantly. In terms of liquidity and leverage, the company holds $4.09M in cash against $6.42M in debt, resulting in a debt-to-equity ratio of 30.32, which suggests a highly leveraged balance sheet with substantial obligations relative to shareholder equity. Despite the debt load, the current ratio stands at 1.71, implying that the company possesses sufficient current assets to cover its short-term liabilities, though the margin of safety is modest given the negative cash flow. Furthermore, the Return on Equity is -6.5% and the Return on Assets is -4.5%, metrics that demonstrate management is currently destroying value rather than generating returns for shareholders or utilizing assets efficiently.
Waarderingsbeoordeling
The trailing P/E ratio and forward P/E ratio are both listed as N/A due to the company's negative earnings, which prevents the calculation of standard earnings-based valuation multiples. Instead, analysts must rely on price-to-book ratio of 0.07, which indicates that the market values the company at a fraction of its net asset value, suggesting a significant discount or potential overvaluation of assets on the balance sheet. Alternative valuation metrics such as the price-to-sales ratio of 0.17 and an EV/EBITDA of -4.29 provide a different perspective, showing that the stock trades at a very low multiple of revenue despite the negative earnings multiple. The 52-week high is recorded at $10800.00, while the 52-week low is $1.05, creating an extreme volatility range where the current price sits in a context of historical instability relative to this specific trading band. The beta value is listed as N/A, meaning there is insufficient historical data to calculate the stock's volatility relative to the broader market, making it difficult to assess systematic risk using standard comparative models. These disparate valuation figures highlight the difficulty in applying traditional valuation frameworks to a company with negative earnings and extreme price fluctuations.
Growth & Income
The revenue growth year-over-year stands at -14.4%, while earnings growth is N/A due to the absence of profitable earnings periods to compare against. The contraction in revenue growth is the primary driver of financial performance, and since earnings are already negative, the concept of earnings growing faster or slower than revenue does not currently apply in a traditional growth sense. As a non-dividend payer, the company has a dividend yield of N/A and a payout ratio of 0.0%, meaning it does not distribute cash to shareholders and retains all earnings, albeit negative ones, which is reinvested into operations rather than paid out. The overall growth and income profile is characterized by declining revenue, negative profitability, and a complete absence of dividend income, reflecting a company in a challenging financial phase that relies on asset sales or new financing rather than organic growth or shareholder returns.